Royalty Report: Drugs, Cancer, Therapeutic – Collection: 29224

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29224

License Grant
The University grants the Licensee an exclusive, worldwide license, with right to sublicense, to make, have made, use, import, market, sell and distribute MP-470 for all diagnostic, prophylactic or therapeutic applications.
License Property
MP-470 is a small-molecule drug, a multi-targeted Tyrosine Kinase inhibitor that may have Rad 51 activity, to treat patients with cancer.

IPSCIO Record ID: 27879

License Grant
Licensors hereby grant to Licensee an exclusive, worldwide license, including the right to sublicense, under Licensor Patent Rights and Future Patent Rights, to make, have made, use, sell, import and export Products.
License Property
Methods for Therapy Sensitization by Inhibition of Jun Kinase Patent Attorney Docket No.: P-UR 2590 (2841302).
Field of Use
The term Field shall mean methods for therapy sensitization by the inhibition of jun kinase and/or the claims specified in the patent application.

IPSCIO Record ID: 35129

License Grant
The Hong Kong Company  granted a co-exclusive, worldwide rights to develop, and exclusive worldwide rights to manufacture and commercialize savolitinib for all diagnostic, prophylactic and therapeutic uses.
License Property
Savolitinib is a potential global first-in-class inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. We developed savolitinib as a potent and highly selective oral inhibitor that was designed to address renal toxicity, the primary issue that has prevented all other selective c-Met inhibitors from gaining regulatory approval. In Phase I clinical studies, savolitinib has shown promising signs of clinical efficacy, causing tumor size reduction in patients with c-Met gene amplification in papillary renal cell carcinoma, non-small cell lung cancer, colorectal cancer and gastric cancer.
Field of Use
This agreement pertains to drugs for all diagnostic, prophylactic and therapeutic uses in the medical industry.

IPSCIO Record ID: 2917

License Grant
The Licensor entered into the License Agreement with the Licensee to develop and commercialize small-molecule mitogen-activated ERK kinase inhibitors for the treatment of cancer. The Licensor granted a worldwide, exclusive License to develop and commercialize our MEK inhibitors for all indications.
License Property
Our lead product candidate from this program, RDEA119, is currently being evaluated both as a single agent and in combination with sorafenib in advanced cancer patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.